Debiopharm Innovation Fund, the Lausanne, Switzerland based strategic investment arm of biopharmaceutical company Debiopharm, announced the launch of its new seed funding initiative.
The program plans to deploy additional capital to support up to 15 seed-stage startups each year. Investments will focus on the next generation of pharma R&D to accelerate drug development, on new technology solutions enabling a more patient-centric approach in clinical trials, and on digital platforms uncovering new insights from clinical data for more personalized care pathways.
The new early stage program, which builds on the fund’s track record of investing in 25 companies since the inception of the fund in 2006, with a focus on Digital Health since 2017, will provide startups with access to capital, knowledge accumulated through years of investing at the intersection of technology, pharma R&D transformation and patient-centric healthcare. Debiopharm also plans to support the most successful startups through their subsequent Series A financing, which will remain the fund’s flagship activity.
Led by Marc Cikes, Managing Director, the fund has already started its activity with two Seed investments, with two more to be announced soon. The first investments include:
- Tune Insight, a Swiss-based startup offering a privacy-preserving data collaboration platform enabling the training of artificial intelligence (AI) models through secure federated learning, and
- Neuroute, a UK-based startup that develops a no-code AI clinical development platform streamlining critical processes of clinical trials, such as study design and site selection.